CagriSema produced an average 15.7% weight reduction in overweight or obese individuals with type 2 diabetes, according to ...

Novo Nordisk (NVO) shares fell nearly 7% premarket on Monday, the most since December, after the drugmaker said its ...

Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was hard to interpret and disappointed investors, but it has a plan to revitalise the programme.

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

Novo Nordisk defends next-gen obesity drug CagriSema, details new trial Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...